Antimicrobial Drug Development: Few Incentives, Many Task Force Meetings
This article was originally published in The Pink Sheet Daily
Executive Summary
The Transatlantic Taskforce on Antimicrobial Resistance's latest report suggests limited progress, but a lack of financial incentives in Europe means companies aren’t innovating in the area.
You may also be interested in...
Antibiotic Incentive Legislation: Can Reimbursement Horn In?
There are two antibiotic incentive bills vying for attention in Congress. One is a follow-on to the popular GAIN Act; the other takes a new path – creating generous reimbursement formulas to help the next wave of anti-infectives find a successful niche in hospital market.
View From ICAAC: How Higher Prices Can Help Save Antibiotic R&D
At the annual anti-infectives meeting, experts consider revamping the business model to spur development of novel antibiotics, with cooperation of regulators in Europe and U.S.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.